3-Year Overall Survival for Patients with Advanced NSCLC Treated with Pembrolizumab

被引：0
|
作者：
Hellmann, Matthew D. [1 ]
Leighl, Natasha B. [2 ]
Hui, Rina [3 ,4 ]
Carcereny, Enric [5 ]
Felip, Enriqueta [6 ,7 ]
Ahn, Myung-Ju [8 ]
Eder, Joseph Paul [9 ]
Balmanoukian, Ani S. [10 ]
Aggarwal, Charu [11 ]
Horn, Leora [12 ]
Patnaik, Amita [13 ]
Gubens, Matthew A. [14 ]
Ramalingam, Suresh S. [15 ]
Lubiniecki, Gregory M. [16 ]
Zhang, Jin [16 ]
Piperdi, Bilal [16 ]
Garon, Edward B. [17 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Westmead Hosp, Sydney, NSW, Australia
[4] Univ Sydney, Sydney, NSW, Australia
[5] Catalan Inst Oncol Badalona, Badalona, Spain
[6] Vall Hebron Univ Hosp, Barcelona, Spain
[7] Vall Hebron Inst Oncol, Barcelona, Spain
[8] Samsung Med Ctr, Seoul, South Korea
[9] Yale Univ, New Haven, CT USA
[10] Angeles Clin & Res Inst, Los Angeles, CA USA
[11] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[12] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[13] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[14] Univ Calif San Francisco, San Francisco, CA 94143 USA
[15] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[16] Merck & Co Inc, Kenilworth, NJ USA
[17] Univ Calif Los Angeles, David Geffen Sch Med, Santa Monica, CA USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2
引用
收藏
页码：60 / 61
页数：2
相关论文
共 50 条
  • [1] KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.
    Leigh, Natasha B.
    Hellmann, Matthew David
    Hui, Rina
    Costa, Enric Carcereny
    Felip, Enriqueta
    Ahn, Myung-Ju
    Eder, Joseph Paul
    Balmanoukian, Ani Sarkis
    Aggarwal, Charu
    Horn, Leora
    Patnaik, Amita
    Gubens, Matthew A.
    Ramalingam, Suresh S.
    Lubiniecki, Gregory M.
    Zhang, Jin
    Piperdi, Bilal
    Garon, Edward B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] 4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.
    Felip, Enriqueta
    Hellmann, Matthew David
    Hui, Rina
    Carcereny, Enric
    Leighl, Natasha B.
    Ahn, Myung-Ju
    Eder, Joseph Paul
    Balmanoukian, Ani Sarkis
    Aggarwal, Charu
    Horn, Leora
    Patnaik, Amita
    Gubens, Matthew A.
    Ramalingam, Suresh S.
    Jensen, Erin
    Kush, Debra A.
    Garon, Edward B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.
    Garon, Edward B.
    Hellmann, Matthew David
    Costa, Enric Carcereny
    Leighl, Natasha B.
    Ahn, Myung-Ju
    Eder, Joseph Paul
    Balmanoukian, Ani Sarkis
    Aggarwal, Charu
    Horn, Leora
    Patnaik, Amita
    Gubens, Matthew A.
    Ramalingam, Suresh S.
    Felip, Enriqueta
    Scalzo, Cathie
    Jensen, Erin
    Kush, Debra A.
    Hui, Rina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
  • [4] Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
    Robert, Caroline
    Ribas, Antoni
    Hamid, Omid
    Daud, Adil
    Wolchok, Jedd D.
    Joshua, Anthony M.
    Hwu, Wen-Jen
    Weber, Jeffrey S.
    Gangadhar, Tara C.
    Joseph, Richard Wayne
    Dronca, Roxana Stefania
    Patnaik, Amita
    Zarour, Hassane M.
    Kefford, Richard
    Hersey, Peter
    Li, Xiaoyun
    Diede, Scott J.
    Ebbinghaus, Scot
    Hodi, F. Stephen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] THREE-YEAR OVERALL SURVIVAL FOR PATIENTS WITH ADVANCED MELANOMA TREATED WITH PEMBROLIZUMAB IN KEYNOTE-001
    Manders, P.
    Joshua, A. M.
    Kefford, R.
    Robert, C.
    Ribas, A.
    Hamid, O.
    Daud, A.
    Wolchok, J. D.
    Hwu, W-J
    Weber, J. S.
    Gangadhar, T. C.
    Joseph, R.
    Dronca, R.
    Patnaik, A.
    Zarour, H.
    Hersey, P.
    Li, X. N.
    Diede, S. J.
    Ebbinghaus, S.
    Hodi, F. S.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 47 - 48
  • [6] Value of total metabolic tumor burden as predictor of overall survival in NSCLC patients treated with pembrolizumab
    Calabro, D.
    Dall'Olio, F. G.
    Formica, F.
    Argalia, G.
    Fanti, S.
    Ardizzoni, A.
    Ambrosini, V.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S567 - S568
  • [7] Pembrolizumab for Previously Treated, PD-L1-Expressing Advanced NSCLC: Real-World Time on Treatment and Overall Survival
    Velcheti, V.
    Chandwani, S.
    Chen, X.
    Piperdi, B.
    Burke, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S882 - S882
  • [8] Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Piperdi, Bilal
    Burke, Thomas
    [J]. CLINICAL LUNG CANCER, 2020, 21 (05) : E445 - E455
  • [9] Heart dose associated. with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy
    Stam, Barbara
    van der Bijl, Erik
    van Diessen, Judi
    Rossi, Maddalena M. G.
    Tijhuis, Angela
    Belderbos, Jose S. A.
    Damen, Eugene
    Sonke, Jan-Jakob
    [J]. RADIOTHERAPY AND ONCOLOGY, 2017, 125 (01) : 62 - 65
  • [10] Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLC
    Lisa Faoro
    Adriana Brusegan
    Alberto Russi
    Vincenzo Calderone
    Alma Martelli
    Ettore Marranconi
    Debora Carpanese
    Elena Berti
    Marina Coppola
    [J]. BMC Pharmacology and Toxicology, 24
12345